7 AG1 Alternatives to Consider in 2026
Its triple GIP/GLP-1/glucagon agonist mechanism produced the most striking weight-loss numbers ever reported in a Phase 2 trial of an injectable peptide, and its broad TRIUMPH Phase 3 program is poised to expand understanding of how triple receptor modulation affects obesity, diabetes, liver disease, cardiovascular risk, sleep apnea, and musculoskeletal health
doi: 10.1016/0014-5793(88)80509-x
Avoid touching needles, syringe tips, vial openings or cleaned rubber stoppers, as contact with fingers or unclean surfaces may introduce microorganisms into the preparation
Body Protection Compound-157 (BPC-157) has similar angiogenic effects to its parent compound, which is instrumental in maintaining healthy intestinal lining and digestive function [1]